- In May 2023, Terumo Corporation announced the global expansion of its LifePearl microspheres, an advanced drug-eluting embolic platform used in TACE procedures for the treatment of hepatocellular carcinoma. The move aims to increase access to precision embolization therapy in new markets, particularly in Asia and Latin America. Terumo’s expansion underscores its commitment to enhancing interventional oncology care by offering innovative, clinically validated solutions that improve patient outcomes in liver cancer management
- In April 2023, Guerbet, a global specialist in diagnostic and interventional imaging, launched its Embozene TANDEM microspheres in Europe, designed for targeted chemoembolization. The product integrates color-coded, drug-loadable microspheres for improved visibility and consistency during TACE procedures. This development aligns with Guerbet’s strategic focus on expanding its interventional oncology portfolio and reinforces its role in advancing minimally invasive cancer therapies
- In March 2023, Boston Scientific Corporation announced the results of a multi-center clinical study evaluating the effectiveness of its Embosphere Microspheres in combination with systemic therapies for intermediate-stage HCC. The study demonstrated improved patient response rates and longer progression-free survival, supporting broader adoption of TACE as part of multimodal treatment strategies. This highlights Boston Scientific's ongoing investment in evidence-based oncology solutions and combination therapy research
- In February 2023, Medtronic partnered with leading cancer institutes in India to introduce training programs focused on interventional oncology techniques, including TACE. This initiative aims to strengthen the skillset of interventional radiologists and expand access to TACE in developing regions. By investing in education and clinical capacity-building, Medtronic is contributing to the wider adoption of minimally invasive treatments and improved liver cancer outcomes across emerging markets
- In January 2023, BTG International (a part of Boston Scientific) received expanded regulatory approval in select European countries for its LC Bead LUMI radiopaque drug-eluting beads, allowing for enhanced visualization during TACE procedures. This innovation facilitates real-time monitoring of embolization, optimizing treatment precision and post-procedure assessment. The development marks a significant advancement in TACE delivery, reinforcing BTG’s commitment to precision medicine in interventional oncology
